Isoindolinone and indazole compounds for the degradation of EGFR

US11673902B2 · kind B2 · utility

Assignee

• C4 THERAPEUTICS, INC.

Inventors

• Christopher G. Nasveschuk · Stoneham, US
• Martin Duplessis · Somerville, US
• Jae Young Ahn · Boston, US
• Alexander Hird · Belmont, US
• Ryan E. Michael · Newton, US
• Kiel Lazarski · Cambridge, US
• Yanke Liang · Belmont, US
• Georg Jaeschke · Basel, CH
• Antonio Ricci · Birsfelden, CH
• Annick Goergler · Basel, CH
• Daniel Rueher · Brochritti, FR

Key dates

• Filing date: Jun 17, 2022
• Grant date: Jun 13, 2023
• Expiry date: Jun 17, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.